340 related articles for article (PubMed ID: 2153235)
1. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Wong ML; Hsu MT
J Virol; 1990 Feb; 64(2):691-9. PubMed ID: 2153235
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase I and II cleavage of adenovirus DNA in vivo: both topoisomerase activities appear to be required for adenovirus DNA replication.
Schaack J; Schedl P; Shenk T
J Virol; 1990 Jan; 64(1):78-85. PubMed ID: 2152835
[TBL] [Abstract][Full Text] [Related]
3. Patterns of strongly protein-associated simian virus 40 DNA replication intermediates resulting from exposures to specific topoisomerase poisons.
Shin CG; Snapka RM
Biochemistry; 1990 Dec; 29(49):10934-9. PubMed ID: 2176889
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of topoisomerase I or II may lead to recombination or to aberrant replication termination on both SV40 and yeast 2 micron DNA.
Levac P; Moss T
Chromosoma; 1996 Oct; 105(4):250-60. PubMed ID: 8854885
[TBL] [Abstract][Full Text] [Related]
5. Transcription of adenovirus and HeLa cell genes in the presence of drugs that inhibit topoisomerase I and II function.
Schaak J; Schedl P; Shenk T
Nucleic Acids Res; 1990 Mar; 18(6):1499-508. PubMed ID: 2158079
[TBL] [Abstract][Full Text] [Related]
6. The in vitro involvement of topoisomerase II in the activity of aza-ellipticine analogues is not correlated with drug activity on isolated nuclei.
Vilarem MJ; Riou JF; Multon E; Gras MP; Larsen CJ
Biochem Pharmacol; 1986 Jul; 35(13):2087-95. PubMed ID: 3015146
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase I and II activities are required for Epstein-Barr virus replication.
Kawanishi M
J Gen Virol; 1993 Oct; 74 ( Pt 10)():2263-8. PubMed ID: 8409949
[TBL] [Abstract][Full Text] [Related]
8. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
9. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
10. Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro.
Ishimi Y; Ishida R; Andoh T
Mol Cell Biol; 1992 Sep; 12(9):4007-14. PubMed ID: 1324412
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin.
Jaxel C; Kohn KW; Pommier Y
Nucleic Acids Res; 1988 Dec; 16(23):11157-70. PubMed ID: 2849758
[TBL] [Abstract][Full Text] [Related]
12. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
13. Pausing sites of RNA polymerase II on actively transcribed genes are enriched in DNA double-stranded breaks.
Singh S; Szlachta K; Manukyan A; Raimer HM; Dinda M; Bekiranov S; Wang YH
J Biol Chem; 2020 Mar; 295(12):3990-4000. PubMed ID: 32029477
[TBL] [Abstract][Full Text] [Related]
14. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
Tewey KM; Chen GL; Nelson EM; Liu LF
J Biol Chem; 1984 Jul; 259(14):9182-7. PubMed ID: 6086625
[TBL] [Abstract][Full Text] [Related]
15. Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and II mediated DNA cleavage: relation to cytotoxicity.
Riou JF; Grondard L; Naudin A; Bailly C
Biochem Pharmacol; 1995 Jul; 50(3):424-8. PubMed ID: 7646545
[TBL] [Abstract][Full Text] [Related]
16. Elongation by RNA polymerase II on chromatin templates requires topoisomerase activity.
Mondal N; Zhang Y; Jonsson Z; Dhar SK; Kannapiran M; Parvin JD
Nucleic Acids Res; 2003 Sep; 31(17):5016-24. PubMed ID: 12930951
[TBL] [Abstract][Full Text] [Related]
17. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
[TBL] [Abstract][Full Text] [Related]
18. Analysis of topoisomerase I and II cleavage sites on the Drosophila actin and Hsp70 heat shock genes.
Kroeger PE; Rowe TC
Biochemistry; 1992 Mar; 31(9):2492-501. PubMed ID: 1312349
[TBL] [Abstract][Full Text] [Related]
19. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
20. Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair.
Stevnsner T; Bohr VA
Carcinogenesis; 1993 Sep; 14(9):1841-50. PubMed ID: 8403208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
